MiNK Therapeutics’ (INKT) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of MiNK Therapeutics (NASDAQ:INKT) in a research note released on Tuesday,Benzinga reports. HC Wainwright currently has a $35.00 price target on the stock.

MiNK Therapeutics Stock Performance

MiNK Therapeutics stock opened at $8.41 on Tuesday. The stock has a 50-day moving average of $8.92 and a two-hundred day moving average of $7.75. MiNK Therapeutics has a one year low of $4.56 and a one year high of $19.00. The stock has a market cap of $33.33 million, a PE ratio of -2.16 and a beta of 0.16.

MiNK Therapeutics (NASDAQ:INKT) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.12). As a group, sell-side analysts predict that MiNK Therapeutics will post -2.75 EPS for the current fiscal year.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.